Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

Abstract: The present invention relates to monoclonal antibodies binding to the N-terminal procollagen (III) propeptide (PIIINP) molecule which is a proteolytic fragment emanating from the specific cleavage of procollagen (III) by N-proteinase after exocytosis and to an assay using these antibodies.

Abstract: In a method of treating a fibrotic disease, a composition is administered to a mammal an effective amount, wherein the composition contains a polypeptide selected from the group consisting of rat, mouse, and human N-terminal procollagen (III) propeptide and rat, mouse, and human C-terminal procollagen (III) propeptide and further contains a pharmaceutically tolerable carrier or dilutant.

Abstract: The present invention concerns novel pyridazine-3-on- and pyrazol-3-on derivatives, methods of synthesizing such, a pharmaceutical agent containing pyridazine-3-on- and pyrazol-3-on derivatives as well as the use of the compounds for the prophylaxis or treatment of fibrotic diseases and/or pathologic remodelling and the use of said compounds for the expansion of stem cells.

Abstract: The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

Abstract: The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex. The algorithm can be used to predict the histological score of a liver biopsy.

Abstract: The invention relates to a method of treating a fibrotic disease, comprising administering to a mammal an effective amount of a phospinate-peptide analog of the general formula (I).

Abstract: The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV/, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP complex. The algorithm can be used to predict the histological score of a liver biopsy.

Abstract: A medicament for treating or preventing fibrotic diseases contains an antifibrotic substance that is a (poly) peptide having antifibrotic activity and comprising at least one of an N-terminal procollagen (III) propeptide and a C-terminal procollagen (III) propeptide, or a fragment of the (poly) peptide defined having antifibrotic activity or a derivative of the (poly) peptide having antifibrotic activity. The antifibrotic substance is combined with a pharmaceutically tolerable carrier or dilutant.